MDMarie-HélÈnE Delfau-Larue

Marie-HélÈnE Delfau-Larue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marie-HélÈnE Delfau-Larue has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Chantal Lahet

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications
  • Eric Lepage

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications
  • Janine Wechsler

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications
  • Jean-Pierre Farcet

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications
  • Liliane Laroche

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications
  • Marianne Asso-Bonnet

    From the Departments of Immunobiology, Pathology, Biostatistics and Medical Informatics, and Dermatology, Hospital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, and University Paris XII, Créteil, France, and the Department of Dermatology, Center of Extracorporeal Photochemotherapy, Hospital Avicennes, Assistance Publique-Hôpitaux de Paris, and University Paris XIII, Bobigny, France

    2 shared publications

Latest Publications

  • Open Access

    Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo

    by Linda Zane, David Sibon, Lionel Jeannin, Marc Zandecki, Marie-Hélène Delfau-Larue, Antoine Gessain, Olivier Gout, Christiane Pinatel, Agnès Lançon, Franck Mortreux, et al.

    Background: Adult T cell leukemia results from the malignant transformation of a CD4+ lymphoid clone carrying an integrated HTLV-1 provirus that has undergone several oncogenic events over a 30-60 year period of persistent clonal expansion. Both CD4+ and CD8+ lymphocytes are infected in vivo; their expansion relies on CD4+ cell cycling and on the prevention of CD8+ cell death. Cloned infected CD4+ but not CD8+ T cells from patients without malignancy also add up nuclear and mitotic defects typical of genetic instability related to theexpression of the virus-encoded oncogene tax. HTLV-1 expression is cancer-prone in vitro, but in vivo numerous selection forces act to maintain T cell homeostasis and are possibly involved in clonal selection. Results: Here we demonstrate that the HTLV-1 associated CD4+ preleukemic phenotype and the specific patterns of CD4+ and CD8+ clonal expansion are in vivo selected processes. By comparing the effects of recent (1 month) experimental infections performed in vitro and those observed in cloned T cells from patients infected for >6-26 years, we found that in chronically HTLV-1 infected individuals, HTLV-1 positive clones are selected for tax expression. In vivo, infected CD4+ cells are positively selected for cell cycling whereas infected CD8+ cells and uninfected CD4+ cells are negatively selected for the same processes. In contrast, the known HTLV-1-dependent prevention of CD8+ T cell death pertains to both in vivo and in vitro infected cells. Conclusions: Therefore, virus-cell interactions alone are not sufficient to initiate early leukemogenesis in vivo.


  • Open Access

    Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma

    by Marie-HélÈnE Delfau-Larue, Liliane Laroche, Janine Wechsler, Eric Lepage, Chantal Lahet, Marianne Asso-Bonnet, Martine Bagot, Jean-Pierre Farcet

    It is now widely accepted that polymerase chain reaction (PCR) analysis of cutaneous T-cell clonality is of diagnostic value in cutaneous T-cell lymphomas (CTCLs) and most helpful in the diagnosis of mycosis fungoides (MF). However, the diagnostic and prognostic value of circulating clonal T cells remains unclear. We studied T-cell clonality in the peripheral blood (PB) and the cutaneous lesion, sampled at the same time, in 363 consecutively seen patients with a clinical suspicion of cutaneous lymphoma. Using a PCR technique providing a specific imprint of T-cell clones (PCRγ–denaturing gradient gel electrophoresis), we found that detection of identical circulating and cutaneous T-cell clones was associated with the diagnosis of CTCL (P < .001). Detection of circulating tumor cells in patients with MF was infrequent (12.5%), except in those with erythrodermic MF (42%; P = .003). Moreover, among the 46 patients who had identical circulating and cutaneous T-cell clones, 25 (56%) had erythroderma. The finding of a dominant clone in the PB but not in the skin was frequent, regardless of the clinicohistologic classification; it occurred in 30% of patients with CTCL, 41% with non-CTCL malignant infiltrates, and 34% with benign infiltrates. This pattern was significantly more frequent in patients over 60 years of age (P < .002), even in the CTCL group (P < .01). In conclusion, dominant T-cell clones detected in the PB of patients with MF by using a routine PCR technique are rarely tumoral and are more often related to age. A multicenter prospective study is under way to establish the prognostic value of circulating tumor cells.


  • Open Access

    Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma

    by Marie-Hélène Delfau-Larue, Liliane Laroche, Janine Wechsler, Eric Lepage, Chantal Lahet, Marianne Asso-Bonnet, Martine Bagot, Jean-Pierre Farcet

    It is now widely accepted that polymerase chain reaction (PCR) analysis of cutaneous T-cell clonality is of diagnostic value in cutaneous T-cell lymphomas (CTCLs) and most helpful in the diagnosis of mycosis fungoides (MF). However, the diagnostic and prognostic value of circulating clonal T cells remains unclear. We studied T-cell clonality in the peripheral blood (PB) and the cutaneous lesion, sampled at the same time, in 363 consecutively seen patients with a clinical suspicion of cutaneous lymphoma. Using a PCR technique providing a specific imprint of T-cell clones (PCRγ–denaturing gradient gel electrophoresis), we found that detection of identical circulating and cutaneous T-cell clones was associated with the diagnosis of CTCL (P < .001). Detection of circulating tumor cells in patients with MF was infrequent (12.5%), except in those with erythrodermic MF (42%; P = .003). Moreover, among the 46 patients who had identical circulating and cutaneous T-cell clones, 25 (56%) had erythroderma. The finding of a dominant clone in the PB but not in the skin was frequent, regardless of the clinicohistologic classification; it occurred in 30% of patients with CTCL, 41% with non-CTCL malignant infiltrates, and 34% with benign infiltrates. This pattern was significantly more frequent in patients over 60 years of age (P < .002), even in the CTCL group (P < .01). In conclusion, dominant T-cell clones detected in the PB of patients with MF by using a routine PCR technique are rarely tumoral and are more often related to age. A multicenter prospective study is under way to establish the prognostic value of circulating tumor cells.